絞り込み

16399

広告

Y(90) ibritumomab tiuxetan with maintenance rituximab as initial therapy for high tumor burden follicular lymphoma: A Wisconsin Oncology Network study.

著者 Thorhildur K , Chang JE , Eickhoff JC , Werndli JE , Kirby RA , Peterson CG , Cole CE , Go RS , Kahl BS
J Clin Oncol.2011 May 20 ; 29(15_suppl):e18503.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (21view , 0users)
e18503 Background: Yttrium(90) ibritumomab tiuxetan (Y(90)IT) radio-immunotherapy has proved to be an effective therapy in relapsed follicular lymphoma (FL). The Wisconsin Oncology Network conducted a clinical trial in which Y(90)IT followed by maintenance rituximab (MR) was evaluated as initial therapy for high tumor burden FL.
PMID: 28023223 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード